Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT01245712

Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation

Status
Active Not Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
200 (actual)
Sponsor
M.D. Anderson Cancer Center · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial studies the side effects and how well radiation therapy works in treating patients with stage 0-II breast cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

Detailed description

PRIMARY OBJECTIVES: I. To assess the cosmesis, acute toxicity and late toxicity in patients treated with accelerated partial breast irradiation delivered with proton radiation. SECONDARY OBJECTIVES: I. To evaluate the convenience of accelerated partial breast irradiation and quality of life during accelerated partial breast irradiation. II. To estimate the in-breast tumor control rates in patients treated with accelerated partial breast irradiation delivered with proton radiation. III. Compare dosimetry to alternate treatment modalities. OUTLINE: Within 10 weeks of last breast cancer surgery, patients undergo accelerated partial breast irradiation (APBI) delivered with proton radiation twice daily (BID) for 5 days. After completion of study treatment, patients are followed up at 6 weeks, 6 months, 1 year, and 18 months, then annually for 10 years.

Conditions

Interventions

TypeNameDescription
RADIATIONAccelerated Partial Breast IrradiationUndergo APBI delivered with proton radiation
RADIATIONProton Beam Radiation TherapyUndergo APBI delivered with proton radiation
OTHERQuality-of-Life AssessmentAncillary studies

Timeline

Start date
2010-11-15
Primary completion
2032-12-31
Completion
2032-12-31
First posted
2010-11-22
Last updated
2025-12-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01245712. Inclusion in this directory is not an endorsement.